[HTML][HTML] NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

T Lakshmikanth, S Burke, TH Ali… - The Journal of …, 2009 - Am Soc Clin Investig
T Lakshmikanth, S Burke, TH Ali, S Kimpfler, F Ursini, L Ruggeri, M Capanni, V Umansky…
The Journal of clinical investigation, 2009Am Soc Clin Investig
NK cells use a variety of receptors to detect abnormal cells, including tumors and their
metastases. However, in the case of melanoma, it remains to be determined what specific
molecular interactions are involved and whether NK cells control metastatic progression
and/or the route of dissemination. Here we show that human melanoma cell lines derived
from LN metastases express ligands for natural cytotoxicity receptors (NCRs) and DNAX
accessory molecule-1 (DNAM-1), two emerging NK cell receptors key for cancer cell …
NK cells use a variety of receptors to detect abnormal cells, including tumors and their metastases. However, in the case of melanoma, it remains to be determined what specific molecular interactions are involved and whether NK cells control metastatic progression and/or the route of dissemination. Here we show that human melanoma cell lines derived from LN metastases express ligands for natural cytotoxicity receptors (NCRs) and DNAX accessory molecule-1 (DNAM-1), two emerging NK cell receptors key for cancer cell recognition, but not NK group 2 member D (NKG2D). Compared with cell lines derived from metastases taken from other anatomical sites, LN metastases were more susceptible to NK cell lysis and preferentially targeted by adoptively transferred NK cells in a xenogeneic model of cell therapy. In mice, DNAM-1 and NCR ligands were also found on spontaneous melanomas and melanoma cell lines. Interference with DNAM-1 and NCRs by antibody blockade or genetic disruption reduced killing of melanoma cells. Taken together, these results show that DNAM-1 and NCRs are critical for NK cell–mediated innate immunity to melanoma cells and provide a background to design NK cell–based immunotherapeutic strategies against melanoma and possibly other tumors.
The Journal of Clinical Investigation